Breaking Finance News

A statement released earlier today by RBC Capital Markets about Galapagos NV GLPG (NYSE:GLPG) bumps the target price to $98.00

Yesterday Galapagos NV GLPG (NYSE:GLPG) traded 1.96% higher at $100.96. The company’s 50-day moving average is $101.59 and its 200-day moving average is $84.97. The last closing price is up 21.76% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 70,350 shares of the stock were exchanged, down from an average trading volume of 92,500

Galapagos NV GLPG (NYSE:GLPG) had its target price raised to $98.00 by RBC Capital Markets in a report released Friday September 15, 2017. The new target price indicates a possible downside of -0.03% based on the company's last closing price.

Previously on 08/11/2017, Stifel Nicolaus reported on Galapagos NV GLPG (NYSE:GLPG) raised the target price from $83.00 to $101.00. At the time, this indicated a possible upside of 0%.

See Chart Below

Galapagos NV GLPG (NYSE:GLPG)

Galapagos NV GLPG has a 52 week low of $57.16 and a 52 week high of $103.54 The company’s market cap is currently $0.

In addition to RBC Capital Markets reporting its target price, a total of 1 broker has issued a report on the stock. The consensus target price is $92.78 with 0 brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Galapagos NV GLPG (NYSE:GLPG)

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.